Home

MG_79412-bn-235x300Prof. Antonio Mazzocca

Antonio Mazzocca is a Faculty Member in the Interdisciplinary Department of Medicine at the University of Bari School of Medicine. Our research focuses on the pathogenic mechanisms of cancer with a particular focus on liver cancer. We are investigating the pathogenic mechanisms underlying processes that sustain the progression of cancer, such as tumor-stromal interactions, tumor infiltration, and metastatic dissemination. The goal is to elucidate mechanisms driving cancer progression, with the ultimate objective of identifying targets for developing drugs interfering with the evolution of the malignant process. Finally, we are combining the experimental approach with a theoretical approach aimed at the complex systems and the evolution to understand the origin and development of cancer.

Office Hours & Location

Students,
Monday – Friday:
10:00 – 11:00 a.m.

Building:
Morgagni 2nd floor,
Policlinico
P.zza Giulio Cesare, 11
70124 Bari

 

To schedule an appointment, please email antonio.mazzocca@uniba.it

2015-2016 Class schedule grids

See attachment or, please, also visit Uniba

Exam information

Timetables, dates and locations, please visit Piattaforma Esse 3

RECENT Publications

A systemic evolutionary approach to cancer: Hepatocarcinogenesis as a paradigm

2016

The systemic evolutionary theory of cancer pathogenesis posits that cancer is generated by the de-emergence of the eukaryotic cell system and by the re-emergence of its archaea (genetic material and cytoplasm) and prokaryotic (mitochondria) subsystems with an uncoordinated behavior.

Read more…

Circulating Levels of PAI-1 Are Predictive of Poor Prognosis in HCC Patients Harboring SERPINE1 4G/4G Polymorphism Undergoing TACE
2015

Although several molecular markers have been proposed as prognostic of disease progression in Hepatocellular carcinoma (HCC), predictive markers of response to treatment are still unsatisfactory. Here, we propose a genetic polymorphism as a potential predictive factor of poor prognosis in HCC patients treated with transcatheter arterial chemoembolization (TACE).

Read more…

Lysophosphatidic Acid Receptor LPAR6 Supports the Tumorigenicity of Hepatocellular Carcinoma
2015

The aberrant processes driving hepatocellular carcinoma (HCC) are not fully understood. Lysophosphatidic acid receptors (LPAR) are commonly overexpressed in HCC, but their contributions to malignant development are not well established. In this report, we show that aberrant expression of LPAR6 sustains tumorigenesis and growth of HCC.

Read more…